Cytokeratin 8 Antibody (1E8): sc-58736

Cytokeratin 8 Antibody (1E8) is a mouse monoclonal IgG2a antibody that detects Cytokeratin 8 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Cytokeratin 8 is a vital component of the cytoskeletal structure in epithelial cells, playing a crucial role in maintaining cellular integrity and providing mechanical support. Cytokeratin 8 is predominantly located in the cytoplasm of simple epithelial cells, where Cytokeratin 8 forms intermediate filaments that contribute to the overall architecture of the tissue. Cytokeratin 8 presence is particularly important in epithelial differentiation and tissue specialization, serving as a marker for various epithelial-derived tumors. Notably, abnormal Cytokeratin 8 expression has been associated with squamous cell carcinomas, indicating a potential role in tumor progression and malignancy. Furthermore, Cytokeratin 8 expression in oral squamous cell carcinomas has been identified as an independent prognostic marker, suggesting that Cytokeratin 8 levels can provide valuable insights into patient outcomes. Unique extracellular Cytokeratin 8 epitopes on tumor cells also present promising targets for therapeutic interventions, making anti-Cytokeratin 8 antibody (1E8) an essential tool for researchers studying epithelial biology and cancer pathology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Cytokeratin 8 Antibody (1E8) References:

1. Cytokeratin 8 silencing in human nasopharyngeal carcinoma cells leads to cisplatin sensitization.  |  Wang, Y., et al. 2008. Cancer Lett. 265: 188-96. PMID: 18353540
2. Full-length cytokeratin 8 is released and circulates in patients with non-small cell lung cancer.  |  Ishii, T., et al. 2008. Tumour Biol. 29: 57-62. PMID: 18497550
3. Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness.  |  Obermajer, N., et al. 2009. Mol Cancer. 8: 88. PMID: 19845941
4. Cytokeratin 8 interacts with clumping factor B: a new possible virulence factor target.  |  Haim, M., et al. 2010. Microbiology (Reading). 156: 3710-3721. PMID: 20817646
5. Cytokeratin 8 is expressed in human corneoconjunctival epithelium, particularly in limbal epithelial cells.  |  Merjava, S., et al. 2011. Invest Ophthalmol Vis Sci. 52: 787-94. PMID: 20926822
6. Disruption of cytokeratin-8 interaction with F508del-CFTR corrects its functional defect.  |  Colas, J., et al. 2012. Hum Mol Genet. 21: 623-34. PMID: 22038833
7. Cytokeratin 8 is increased in hepatitis C virus cells and its ectopic expression induces apoptosis of SMMC7721 cells.  |  Sun, MZ., et al. 2013. World J Gastroenterol. 19: 6178-87. PMID: 24115814
8. Cytokeratin 8 is an epithelial cell receptor for Pet, a cytotoxic serine protease autotransporter of Enterobacteriaceae.  |  Nava-Acosta, R. and Navarro-Garcia, F. 2013. mBio. 4: e00838-13. PMID: 24327340
9. Cytokeratin-8 in Anaplastic Thyroid Carcinoma: More Than a Simple Structural Cytoskeletal Protein.  |  Guo, D., et al. 2018. Int J Mol Sci. 19: PMID: 29443941
10. Knockdown of cytokeratin 8 overcomes chemoresistance of chordoma cells by aggravating endoplasmic reticulum stress through PERK/eIF2α arm of unfolded protein response and blocking autophagy.  |  Wang, D., et al. 2019. Cell Death Dis. 10: 887. PMID: 31767864

The preferred Cytokeratin 8 antibody is Cytokeratin 8 Antibody (C51): sc-8020.